Introduction: Pulmonary arteriovenous fistula (PAVF) is an abnormal intrapulmonary right-to-left shunt. About 1 in 4 patients with untreated PAVF may suffer a paradoxical embolic acute ischemic stroke (AIS) by 65 years of age. Current expert recommendations are to treat all CT scan visible PAVF, even if asymptomatic. The American Heart Association Stroke Guidelines recommend using antiplatelet agents for secondary prophylaxis of AIS related to PAVF. Objective: To determine from the Nationwide Inpatient Sample (NIS), the prevelance and management trends of AIS in patients diagnosed with PAVF. Methods: Using the NIS from 2001-2014, patients carrying a secondary diagnosis of PAVF (ICD-9 CM code: 417.0) and a subsequent hospitalization with AIS were identified. SAS 9.4 was used for data analysis with categorical and continuous variables tested using the Chi-Square test of proportions and Student’s t-test, respectively. Cox proportional hazard regression was used to adjust for confounders. Results: A total of 4430 (weighted) patients (>18 years) were diagnosed with PAVF at a mean age of 55.6 years (SE±0.7). About 7% (n=312, p<0.0001) patients with PAVF were admitted with AIS at a mean age of 58.5 years (SE ±2.5). From 2001 to 2014, there was a two-fold increase in the prevalence of PAVF (204 vs. 455) as well as AIS related admissions (5% vs. 12%). On univariate analysis, epistaxis (p= 0.0184 OR 5.7), migraine (p= 0.0007, OR 5.7), patent foramen ovale (PFO) (p=0.0002, OR 3.2) and cannabis use (p= 0.009, OR 5.8) were significantly associated with AIS. Migraine (p=0.0062, OR 4.17) and PFO (p=0.0004, OR 3.68) retained significance on multivariate analysis. None of the ischemic strokes received reperfusion therapy. Only about 8% (n=24) were on long-term antiplatelet therapy. Approximately 3.2% (n= 141) of all patients with PAVF had a percutaneous embolization of their fistula. Conclusion: In a nationally representative sample, the prevalence of AIS in patients with PAVF has roughly doubled from 2001 to 2014. Utilization of reperfusion therapy and secondary stroke prophylaxis with antiplatelet agents is low. Consensus guidelines and randomized control trials are need to establish the role of fistula embolization in these patients.